Cargando…

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma

Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tengfei, Wiggins, Chad C., Kornatowski, Breanna M., Hailat, Ra'ed S., Clayburn, Andrew J., Guo, Winston L., Johnson, Patrick W., Senefeld, Jonathon W., Klassen, Stephen A., Baker, Sarah E., Bruno, Katelyn A., Fairweather, DeLisa, Wright, R. Scott, Carter, Rickey E., Li, Chenxi, Joyner, Michael J., Paneth, Nigel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826061/
https://www.ncbi.nlm.nih.gov/pubmed/35155458
http://dx.doi.org/10.3389/fmed.2021.707895
_version_ 1784647353115869184
author Ma, Tengfei
Wiggins, Chad C.
Kornatowski, Breanna M.
Hailat, Ra'ed S.
Clayburn, Andrew J.
Guo, Winston L.
Johnson, Patrick W.
Senefeld, Jonathon W.
Klassen, Stephen A.
Baker, Sarah E.
Bruno, Katelyn A.
Fairweather, DeLisa
Wright, R. Scott
Carter, Rickey E.
Li, Chenxi
Joyner, Michael J.
Paneth, Nigel S.
author_facet Ma, Tengfei
Wiggins, Chad C.
Kornatowski, Breanna M.
Hailat, Ra'ed S.
Clayburn, Andrew J.
Guo, Winston L.
Johnson, Patrick W.
Senefeld, Jonathon W.
Klassen, Stephen A.
Baker, Sarah E.
Bruno, Katelyn A.
Fairweather, DeLisa
Wright, R. Scott
Carter, Rickey E.
Li, Chenxi
Joyner, Michael J.
Paneth, Nigel S.
author_sort Ma, Tengfei
collection PubMed
description Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients.
format Online
Article
Text
id pubmed-8826061
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88260612022-02-10 The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma Ma, Tengfei Wiggins, Chad C. Kornatowski, Breanna M. Hailat, Ra'ed S. Clayburn, Andrew J. Guo, Winston L. Johnson, Patrick W. Senefeld, Jonathon W. Klassen, Stephen A. Baker, Sarah E. Bruno, Katelyn A. Fairweather, DeLisa Wright, R. Scott Carter, Rickey E. Li, Chenxi Joyner, Michael J. Paneth, Nigel S. Front Med (Lausanne) Medicine Treatment of patients with COVID-19 using convalescent plasma from recently recovered patients has been shown to be safe, but the time course of change in clinical status following plasma transfusion in relation to baseline disease severity has not yet been described. We analyzed short, descriptive daily reports of patient status in 7,180 hospitalized recipients of COVID-19 convalescent plasma in the Mayo Clinic Expanded Access Program. We assessed, from the day following transfusion, whether the patient was categorized by his or her physician as better, worse or unchanged compared to the day before, and whether, on the reporting day, the patient received mechanical ventilation, was in the ICU, had died or had been discharged. Most patients improved following transfusion, but clinical improvement was most notable in mild to moderately ill patients. Patients classified as severely ill upon enrollment improved, but not as rapidly, while patients classified as critically ill/end-stage and patients on ventilators showed worsening of disease status even after treatment with convalescent plasma. Patients age 80 and over showed little or no clinical improvement following transfusion. Clinical status at the time of convalescent plasma treatment and age appear to be the primary factors in determining the therapeutic effectiveness of COVID-19 convalescent plasma among hospitalized patients. Frontiers Media S.A. 2022-01-26 /pmc/articles/PMC8826061/ /pubmed/35155458 http://dx.doi.org/10.3389/fmed.2021.707895 Text en Copyright © 2022 Ma, Wiggins, Kornatowski, Hailat, Clayburn, Guo, Johnson, Senefeld, Klassen, Baker, Bruno, Fairweather, Wright, Carter, Li, Joyner and Paneth. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Ma, Tengfei
Wiggins, Chad C.
Kornatowski, Breanna M.
Hailat, Ra'ed S.
Clayburn, Andrew J.
Guo, Winston L.
Johnson, Patrick W.
Senefeld, Jonathon W.
Klassen, Stephen A.
Baker, Sarah E.
Bruno, Katelyn A.
Fairweather, DeLisa
Wright, R. Scott
Carter, Rickey E.
Li, Chenxi
Joyner, Michael J.
Paneth, Nigel S.
The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
title The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
title_full The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
title_fullStr The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
title_full_unstemmed The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
title_short The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
title_sort role of disease severity and demographics in the clinical course of covid-19 patients treated with convalescent plasma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826061/
https://www.ncbi.nlm.nih.gov/pubmed/35155458
http://dx.doi.org/10.3389/fmed.2021.707895
work_keys_str_mv AT matengfei theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT wigginschadc theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT kornatowskibreannam theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT hailatraeds theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT clayburnandrewj theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT guowinstonl theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT johnsonpatrickw theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT senefeldjonathonw theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT klassenstephena theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT bakersarahe theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT brunokatelyna theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT fairweatherdelisa theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT wrightrscott theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT carterrickeye theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT lichenxi theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT joynermichaelj theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT panethnigels theroleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT matengfei roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT wigginschadc roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT kornatowskibreannam roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT hailatraeds roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT clayburnandrewj roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT guowinstonl roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT johnsonpatrickw roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT senefeldjonathonw roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT klassenstephena roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT bakersarahe roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT brunokatelyna roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT fairweatherdelisa roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT wrightrscott roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT carterrickeye roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT lichenxi roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT joynermichaelj roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma
AT panethnigels roleofdiseaseseverityanddemographicsintheclinicalcourseofcovid19patientstreatedwithconvalescentplasma